Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 21,700 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 21,700 shares of Enliven Therapeutics stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $24.18, for a total transaction of $524,706.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Anish Patel also recently made the following trade(s):

• On Friday, October 18th, Anish Patel sold 716 shares of Enliven Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $21,480.00.

Enliven Therapeutics Stock Down 10.0 %

ELVN stock opened at $21.74 on Friday. The business’s 50-day simple moving average is $24.54 and its 200 day simple moving average is $24.39. The company has a market cap of $1.06 billion, a PE ratio of -11.44 and a beta of 1.04. Enliven Therapeutics, Inc. has a twelve month low of $10.90 and a twelve month high of $30.03.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ELVN shares. Robert W. Baird increased their target price on Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. Finally, BTIG Research initiated coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective on the stock. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $38.25.

Institutional Trading of Enliven Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ELVN. FMR LLC lifted its position in Enliven Therapeutics by 10.6% in the third quarter. FMR LLC now owns 6,296,179 shares of the company’s stock worth $160,804,000 after purchasing an additional 601,611 shares during the period. First Turn Management LLC bought a new position in shares of Enliven Therapeutics during the 2nd quarter worth about $9,657,000. Lord Abbett & CO. LLC acquired a new stake in shares of Enliven Therapeutics during the 3rd quarter valued at about $8,199,000. Janus Henderson Group PLC increased its stake in Enliven Therapeutics by 43.0% in the third quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock valued at $26,611,000 after acquiring an additional 313,019 shares during the period. Finally, Ally Bridge Group NY LLC acquired a new position in Enliven Therapeutics in the third quarter worth about $5,998,000. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.